Sign in
Not yet taking people in United StatesNo phase

Smart pill bottle cap to help people with serious lung diseases take medicines

Tests a smart bottle cap in people with lung fibrosis, sarcoidosis or pulmonary hypertension.

Key facts

Who runs it
Cosmos Rx, Inc
Where
Norfolk, United StatesSee the site
Trial code
Registry title
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
Status
Not yet recruiting
People taking part
100 people, planned
Started
Jul 2026
Expected to end
Aug 2027
Type of study
Observational, 2 groups
Record updated
29 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a lung disease such as interstitial lung disease, sarcoidosis or pulmonary hypertension who take their own pills and can use a smart pill-bottle cap for nine months.

Age
21 years or older
Sex
All sexes can join
Disease stage
Main diagnosis of interstitial lung disease (including sarcoidosis) and/or pulmonary hypertension
Earlier treatment
Already taking, or about to start with insurance approval, at least one pill for interstitial lung disease or pulmonary hypertension
Biomarker or test result
6-Minute Walk Test scheduled within 30 days or done in the past 30 days. Interstitial lung disease: FVC and/or DLCO scheduled within 30 days or done in the past 90 days. Pulmonary hypertension: heart echocardiogram scheduled within 30 days or done in the past 90 days

Main reasons for not taking part

  • Needing a caregiver to give the medication
  • No daily access to a smartphone that works with the FORTISKAP™ app
  • Not proficient in English
  • Not meeting any one of the inclusion criteria

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • 21 years of age or older at time of enrollment
  • Primary diagnosis of interstitial lung disease (including sarcoidosis) AND/OR pulmonary hypertension
  • Currently managing their oral medications independently (i.e., without requiring caregiver administration)
  • At least one oral medication with a primary indication for treatment of ILD or PH already in use, or planned for initiation with insurance approval secured, at the time of enrollment
  • 6-Minute Walk Test (6MWT) scheduled within the next 30 days or performed within the past 30 days
  • For ILD subjects: FVC and/or DLCO scheduled within the next 30 days or performed within the past 90 days
  • For PH subjects: Cardiac echocardiography scheduled within the next 30 days or performed within the past 90 days
  • Daily access to a smartphone compatible with the FORTISKAP™ companion application
  • Proficient in English

Who cannot take part

  • Failure to meet any one of the above inclusion criteria

Where in United States

  • Pulmonary Disease Clinic, Sentara Norfolk HospitalNorfolk, United StatesContact: Matthew Bernens, MDNot yet recruiting

About the trial

What the trial wants to find out

This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks prescription bottle openings and sends dose reminders to participants and their care team - take their medications more consistently and experience better health outcomes compared to similar participants receiving standard care without the device. Participation requires no changes to prescribed medications, testing or clinical visits beyond what is already part of routine care; participants use a modified medication bottle equipped with the FORTISKAP™ cap for nine months.

The 2 groups in the trial

  • Fortiskap Group

    Prospective Cohort equipped with medication adherence monitoring device

  • Historical Controls

    Historical Control group (retrospective cohort)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
Plain-language title
Smart pill bottle cap to help people with serious lung diseases take medicinesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
29 May 2026